There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intercept Pharma (NASDAQ:ICPT), Adamas Pharmaceuticals (NASDAQ:ADMS) and Adverum Biotechnologies (NASDAQ:ADVM) with bullish sentiments.
Intercept Pharma (ICPT)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Intercept Pharma yesterday and set a price target of $120. The company’s shares closed yesterday at $105.86.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 26.2% and a 49.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Currently, the analyst consensus on Intercept Pharma is a Moderate Buy with an average price target of $137.78, which is a 30.2% upside from current levels. In a report issued on October 31, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $170 price target.
.
See today’s analyst top recommended stocks >>
Adamas Pharmaceuticals (ADMS)
In a report released yesterday, Ken Cacciatore from Cowen & Co. maintained a Buy rating on Adamas Pharmaceuticals, with a price target of $30. The company’s shares closed yesterday at $16.97, close to its 52-week low of $15.03.
According to TipRanks.com, Cacciatore is a 3-star analyst with an average return of 2.8% and a 44.7% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Liquidia Technologies Inc, Amag Pharmaceuticals, and Revance Therapeutics.
Adamas Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $43.75.
Adverum Biotechnologies (ADVM)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Adverum Biotechnologies yesterday. The company’s shares closed yesterday at $4.55.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.9% and a 50.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adverum Biotechnologies with a $10.75 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
